Skip to content

Validation of the MedHub AutocathFFR Software Device for Non-Invasive Fractional Flow Reserve (FFR)

MedHub AutocathFFR United States Validation Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07763769
Enrollment
277
Registered
2026-08-13
Start date
2025-11-04
Completion date
2026-06-29
Last updated
2026-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease, Non-ST-Elevation Myocardial Infarction, Stable Angina, Unstable Angina

Keywords

Fractional Flow Reserve, FFR, AutocathFFR, Coronary Angiography

Brief summary

This observational study evaluated how well the AutocathFFR software measures fractional flow reserve (FFR) from coronary angiogram images. AutocathFFR runs on standard two-dimensional (2D) angiograms taken during cardiac catheterization. Researchers compared its results to invasive FFR, the gold standard. The main questions were: * What is the sensitivity of AutocathFFR per vessel compared to invasive FFR? * What is the specificity of AutocathFFR per vessel compared to invasive FFR? A vessel is scored "positive" when FFR ≤ 0.80 and "negative" when FFR \> 0.80. Researchers retrospectively analyzed consecutive angiograms from 4 sites in the United States. 278 patients (300 vessels) were analyzed with the AutocathFFR software, and 277 patients (297 vessels) completed AutocathFFR analysis. Participants were adults with stable angina, unstable angina, or non-ST-elevation myocardial infarction (NSTEMI) who underwent invasive coronary angiography and invasive FFR.

Interventions

DEVICEMedHub AutocathFFR

MedHub AutocathFFR is a software device for the analysis of previously acquired angiography data in Digital Imaging and Communications in Medicine (DICOM) format. The AutocathFFR value is computed from standard 2D angiography images, taken from two different views, retrieved from the C-arm angiography system. The FFR value is calculated using a machine-learning and computer vision algorithm. The result is intended to support the functional evaluation of coronary artery disease.

Sponsors

Medhub Ltd.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
23 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \> 22 years * Subjects with stable angina pectoris, unstable angina pectoris, or NSTEMI and in whom invasive FFR was performed to assess a non-culprit stenosis in at least one coronary artery * Subject underwent a clinically indicated Invasive Coronary Angiogram (ICA) * Subject underwent invasive FFR with intravenous (IV) or intracoronary adenosine, or adenosine triphosphate (ATP), as hyperemic stimulus

Exclusion criteria

* Angiogram not obtained on a United States Food and Drug Administration (FDA)-cleared C-arm angiography system * Invasive FFR not obtained on an FDA-cleared FFR catheter tip pressure transducer (also known as a pressure wire) * Vessel size less than 2 mm * Subject presents with an ST-elevation myocardial infarction (STEMI) * Chronic total occlusion (CTO) in target vessel * Prior coronary artery bypass graft (CABG) surgery, heart transplant or valve surgery, prior transcatheter aortic valve implantation/replacement (TAVI/TAVR), or severe left-sided valvular disease * Known left ventricular ejection fraction (LVEF) ≤ 30% * Arteries supplying akinetic or severe hypokinetic territories on target lesion, if already known based on prior imaging * Thrombolysis in Myocardial Infarction (TIMI) flow grade equal to or lower than 2 at baseline * Target lesion involves Left Main (stenosis \>50%) * Percutaneous coronary intervention (PCI) with stent in target vessel in past 12 months, or target vessel involves in-stent restenosis * Target coronary vessel provides collaterals to a chronically occluded vessel * Coronary angiography was not performed per standard of care at a cine frame rate of at least 7 frames per second * Presence of aortic damping * Distortion of the waveform * Less than two different angiographic views for each lesion of interest in the Left Circumflex Artery (LCX), Left Anterior Descending Artery (LAD), or Right Coronary Artery (RCA) * Lesion is not clearly visible

Design outcomes

Primary

MeasureTime frameDescription
Per-Vessel Sensitivity of AutocathFFR vs. Invasive FFRDay 1 (the day of the index invasive coronary angiography procedure)Sensitivity of the dichotomously scored AutocathFFR per vessel compared to the gold standard, invasive FFR measurements, where an FFR ≤ 0.80 is scored "positive" and an FFR \> 0.80 is considered "negative". Performance goal: lower bound of one-sided 97.5% confidence interval must exceed 80%.
Per-Vessel Specificity of AutocathFFR vs. Invasive FFRDay 1 (the day of the index invasive coronary angiography procedure)Specificity of the dichotomously scored AutocathFFR per vessel compared to the gold standard, invasive FFR measurements, where an FFR ≤ 0.80 is scored "positive" and an FFR \> 0.80 is considered "negative". Performance goal: lower bound of one-sided 97.5% confidence interval must exceed 80%.

Secondary

MeasureTime frameDescription
Per-Patient Sensitivity and SpecificityDay 1 (the day of the index invasive coronary angiography procedure)Per-patient sensitivity and specificity of the dichotomously scored AutocathFFR per vessel compared to gold standard, invasive FFR, where an FFR ≤ 0.80 is scored "positive" and an FFR \> 0.80 is considered "negative".
Sensitivity, Specificity, PPV, and NPV Including "No FFR" OutputDay 1 (the day of the index invasive coronary angiography procedure)Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of AutocathFFR, including cases where the device produces a "No FFR" output (failure to compute), compared to the gold standard, invasive FFR.
Device Success RateThrough study completion, up to 8 monthsDevice success, measured as the ratio of completed versus initiated AutocathFFR index calculations.
Device-Related MalfunctionsThrough study completion, up to 8 monthsNumber of device-related malfunctions recorded throughout the study, summarized descriptively.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORHector M. Garcia-Garcia, MD

Medstar Health Research Institute

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 14, 2026